None listed
Conditions
Interventions
DURING THE VISIT OF THE WEEK 48, PARTICIPANTS PASSED TO A PERIOD OF 48 WEEKS OF MONITORING TREATMENT AND CARE NOT PROVIDED BY THE STUDY, WITH A TOTAL LENGTH STUDY OF 96 WEEKS.
THE MAIN ASSESSMENT C
25 cells / mm ³) AND THE PRESENCE OF POOR PROGNOSIS FACTORS (IE, NO ALL VS. PRESENCE OF AT LEAST ONE OF THE FOLLOWING: HOSPITAL REPORTABLE WITHIN 30 DAYS PRIOR, BMI <18.5 OR ANEMIA [HB <8 G / DL]).
Sponsors
El Instituto Nacional de Alergia y Enfermedades Infecciosas (NIAID) de los Estados Unidos,
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 4.1.1 HIV-1 INFECTION, DOCUMENTED BY ANY LICENSED RAPID HIV TEST OR HIV ENZYME OR CHEMILUMINESCENCE IMMUNOASSAY FOR HIV (E/CIA) TEST KIT AT ANY TIME PRIOR TO STUDY ENTRY AND CONFIRMED BY A KICENSED WESTERN BLOT OR A SECOND ANTIBODY TEST BY A METHOD OTHER THAN THE INITIAL RAPID HIV TEST AND/OR E/CIA, OR BY HIV-1 ANTIGEN, PLASMA HIV-1 RNA VIRAL LOAD. THE WHO AND THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) GUIDELINES MANDATE THAT CONFIRMATION OF THE INITIAL TEST RESULT MUST USE A TEST THAT IS DIFFERENT FROM THE ONE USED FOR THE INITIAL ASSESSMENT. A REACTIVE INITIAL RAPID TEST SHOULD BE CONFIRMED BY EITHER ANOTHER TYPE OF RAPID ASSAY OR AN E/CIA THAT IS BASED ON A DIFFERENT ANTIGEN PREPARATION AND/OR DIFFERENT TEST PRINCIPLE (eg, INDIRECT VERSUS COMPETITIVE), OR A WESTERN BLOT OR A PLASMA HIV-1 RNA VIRAL LOAD. NOTE: THE TERM LICENSED REFERS TO A KIT THAT HAS BEEN CERTIFIED OR LICENSED BY AN OVERSIGHT BODY WITHIN THE COUNTRY IN WHICH IT IS USED AND HAS BEEN VALIDATED INTERNALLY. 4.1.2 WILLINGNESS TO START EFAVIRENZ-BASED ART AS SOON AS POSSIBLE AND WITHIN NO MORE THAN THREE DAYS FOLLOWING RANDOMIZATION. 4.1.3 CD4 + CELL COUNT <50 CELLS / MM ³ OBTAINED WITHIN 45 DAYS PRIOR TO STUDY ENTRY AT ANY LABORATORY THAT HAS A CLIA CERTIFICATION OR ITS EQUIVALENT.
Exclusion criteria
Exclusion criteria: 4.2.1 WITHIN 30 DAYS PRIOR TO THE STUDY OF INCOME AND AFTER COMPLETING THE SPECIFIC DETECTION ALGORITHM STUDY (SEE SECTION 4.3.6), THE PRESENCE OF ANY CONFIRMED OR PROBABLE TB BASED CRITERIA LISTED IN THE APPENDIX ACTG CURRENT DIAGNOSIS, WHICH IS IDENTIFIED IN THE CRF. 4.2.2 USE OF SINGLE DOSE NVP FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (pMTCT) WITHIN 24 MONTHS PRIOR TO STUDY ENTRY. NOTE: COMBINATION ANTIRETROVIRALS (ARVs) TAKEN FOR ANY LENGTH DURING PREGNANCY FOR pMTCT EXCLUSIONARY. 4.2.3 USE OF PROHIBITED MEDICATIONS (SEE LIST IN THE A5274/REMEMBER MOPS, SECTION 3.2.1) WITHIN 30 DAYS PRIOR TO STUDY ENTRY. 4.2.4 KNOWN ALLERGY / SENSITIVITY OR ANY HYPERSENSITIVITY TO COMPONENTS OF STUDY-REQUIRED ART OR TB TREATMENT. 4.2.5 CURRENT RECEIPT OF TREATMENT FOR ACTIVE TB OR RECEIPT OF > 14 DAYS CUMULATIVE TREATMENT FOR ACTIVE TB WITHIN 96 WEEKS PRIOR TO STUDY ENTRY. 4.2.6 RECEIPT OF > 30 DAYS CUMULATIVE OF INH PROPHYLAXIS WITHIN 48 WEEKS PRIOR TO STUDY ENTRY.
Countries
Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Tanzania, Zimbabwe
Outcome results
None listed